Early Breast Cancer Detection Articles & Analysis
14 articles found
Exosomes, small vesicles released by cells, play an increasingly prominent role in intercellular communication and disease modulation. These nano-sized particles contain a diverse array of molecular cargo, including proteins, lipids, RNA, and metabolites, which serve as biomarkers for a variety of physiological conditions. Exosome lipidomics and metabolomics are key fields that focus on profiling ...
Alfa Cytology has announced cancer diagnostic biomarker development services to enhance precision in oncology research. Alfa Cytology, a pioneering biotech firm comprising an interdisciplinary team of scientists, bioinformaticians, and oncologists, has recently introduced its cancer diagnostic biomarker development services to advance personalized cancer treatment strategies. Cancer diagnosis ...
CDH1 acts as a tumor suppressor by inhibiting the Wnt/β-catenin pathway, which is often dysregulated in cancer. What is the role of CDH1 in cancer? The loss or dysfunction of CDH1 has been implicated in the development and progression of various types of cancer. ...
Nano-flow cytometry is a revolutionary technology that has the potential to transform early disease detection and diagnosis. Nano-flow cytometers are able to detect and analyze individual nanoparticles, including extracellular vesicles and viruses, with high sensitivity and accuracy. This makes them ideal for detecting diseases at their earliest stages, when they are most treatable. How does ...
All three companies are excited to bring such a product into the market with one goal—improving early breast cancer detection. Day 2 Technical training for Datascan engineers continued on the mobile unit. ...
This is an observational cohort study looking at women, 30 years of age or older with a concern or at risk of suspected breast disease or breast cancer. The proposed study aims to examine the diagnostic performance of non-contrast MRI in breast disease by applying quantitative multiparametric MRI ...
#CancelEverything On March 11, 2020, the World Health Organization (WHO) declared the coronavirus 2019 disease (COVID-19) a global pandemic. Its impact left the world uncertain about health, politics and the economy. The first wave caused a major disruption to health services, exacerbating concerns of patient and physician safety and resource availability. On trend with the “cancel ...
VisionGate’s Non-Intrusive Testing, Patented Cell-CT Imaging and AI-Powered Cancer Detection Work Together to Deliver Early Detection of Lung Cancer. VisionGate’s mission is backed by cutting-edge technology that is designed to save lives through early detection and prevention of lung cancer. VisionGate’s breakthrough technologies include non-intrusive testing, 3D cell imaging ...
As Phoenix’s bioscience initiative grows, so do job opportunities for students By the end of the year, over $3 billion will have been invested into Phoenix’s bioscience and healthcare facilities, creating more than 8,000 jobs Phoenix City Council voted to fund the Bioscience Healthcare Strategic Initiative for the 2021-2022 fiscal year last Tuesday, a plan set to help create new job ...
ByCalviri
VisionGate, a Breakthrough Liquid-biopsy Technology Company, Leads the Battle Against Lung Cancer through Early Detection Technology with a Simple, Non-Intrusive Sputum Test. VisionGate wants you to live your life with peace of mind. That’s why we’ve launched a new website that makes it easy for you to learn more about our advanced lung cancer detection technology. Our new site ...
This is evident in the countless women who are still misdiagnosed – either receiving a false positive or getting diagnosed in the later stages of the disease. Why Early Detection is Important According to the National Breast Cancer Foundation, if breast cancer is still ...
A study of Universal Diagnostics' blood-based colorectal cancer test found it was more than 90 percent accurate, the company announced June 3. The blood test was found to detect colorectal cancer with 92 percent sensitivity and 97 percent specificity. It also was shown to have 89 percent sensitivity and 97 percent specificity detecting early-stage cancer. The test uses single target sequence ...
SEVILLE, Spain--(BUSINESS WIRE)--Universal Diagnostics (UDX), an in-vitro diagnostics company developing minimally-invasive, blood-based solutions for detecting cancer early, announced today that it has started a prospective, multi-center observational study in the US for its investigational advanced adenoma (precursor lesions) and colorectal cancer (CRC) detection blood test. UDX is performing ...
Abstract Purpose: SelectMDx (MDxHealth®) is a panel of urinary biomarkers used in conjunction with traditional risk factors to individualize risk prediction for clinically significant prostate cancer. In this study we sought to characterize the effectiveness of SelectMDx in a population of American men with elevated prostate specific antigen. Materials and methods: We developed a ...